Search results for #KEYNOTE564
Today on #MashupMD, our editors revisit the #RCC roundtables from #GU24 and bring you the latest research in #GUOncology with the help of our friends at @GUOncologyNow. Check out essential reading on IO/IO vs. IO/TK treatment, #KEYNOTE564, and more: --- mashupmd.com/expert-collect…
👀 #ICYMI: @DrChoueiri and colleagues reported long-term results from the #KEYNOTE564 study showing #OS improvement in patients with #ccRCC who received #adjuvant #pembrolizumab. 🧠 Learn More: buff.ly/42pWPq3
Han salido los resultados de supervivencia global del #KEYNOTE564 📜#pembrolizumab adyuvante en el #carcinomadecelulasrenales. Échales un vistazo 🔎oncobites.tv/gunews/keynote…
Such important data for patients with RCC! #KEYNOTE564 Congratulations @DrChoueiri @tompowles1 and all investigators! @NEJM
Such important data for patients with RCC! #KEYNOTE564 Congratulations @DrChoueiri @tompowles1 and all investigators! @NEJM
Overall survival has been hard to show in #kidneycancer. Grateful to have contributed to #Keynote564 while @DukeGUCancer and on pub w @DrChoueiri @tompowles1 @HHammersMD and global team!! Congrats ultimately to our patients who were on the trial & who now benefit. 🤩 @utswcancer
Overall survival has been hard to show in #kidneycancer. Grateful to have contributed to #Keynote564 while @DukeGUCancer and on pub w @DrChoueiri @tompowles1 @HHammersMD and global team!! Congrats ultimately to our patients who were on the trial & who now benefit. 🤩 @utswcancer
2/After 50 years of adjuvant trials on RCC (3 slides); #KEYNOTE564 demonstrates overall survival (OS) benefit!
@CaPsurvivorship sits down with @DrChoueiri to discuss the results of the #KEYNOTE564 trial marking a significant milestone in #KidneyCancer treatment and a critical discussion point for clinicians and patients > bit.ly/4a3Ydlz
🎥 Professor Stefan N. Symeonides shares his insights on the #KEYNOTE564 trial and the new data presented on overall survival at ASCO #GU24. -> medicaldigest.org/scientific-con… @EdiCancerCentre @ASCO #KidneyCancer #oncology #MedTwitter
👀 #ICYMI: @Daniel_J_George provides a comprehensive overview of the #adjuvant #pembrolizumab long-term data from #KEYNOTE564. 🎥 Watch Here: buff.ly/3TNYDqg
@CaPsurvivorship sits down with @DrChoueiri to discuss the results of the #KEYNOTE564 trial marking a significant milestone in #KidneyCancer treatment and a critical discussion point for clinicians and patients > bit.ly/4a3Ydlz
💡 Catch the next installment of our discussion with @Daniel_J_George of @DukeHealth, @DukeCancer for #KidneyCancerAwareness month: 🎙️ Dr. George highlights #KEYNOTE564 and other adjuvant approaches for patients with #RCC. 📺 Watch Now: buff.ly/3V5huOB
🗞️Don't miss the latest updates in #GUOncology, catch up on our top posts from February! 🔬 @tompowles1 explained the latest #KidneyCancer updates including long-term results from #KEYNOTE564 and the future of #adjuvant treatment. 📺 Watch Now: buff.ly/3uwhJYl
🌟 Catch our latest video with @tompowles1 discussing #KEYNOTE564, #CheckMate9ER, and more #RCC updates! 🌟 Watch now: buff.ly/3uwhJYl
Watch our expert discussions on notable trials presented at the ASCO GU Symposium around bladder, kidney and prostate cancer. ow.ly/8Bq650QAgnY #AMBASSADOR #BRCAAway #CheckMate914 #CONTACT2 #EV302 #GETUG-AFU18 #Keynote564 #SCNivolumab #GUCancer #MedOnc #OncEd #Oncology
🎥 Professor David F. McDermott shares his insights on the #KEYNOTE564 trial and the new data presented on overall survival at ASCO #GU24. -> medicaldigest.org/scientific-con… @harvardmed @BIDMChealth @ASCO #KidneyCancer #oncology #MedTwitter